Multivalent molecules comprising DR5-binding domains

A multivalent DR5-binding molecule having a VL Domain comprising a CDRL1 Domain, a CDRL2 Domain, and a CDRL3 Domain, and a VH Domain comprising a CDRH1 Domain, a CDRH2 Domain and a CDRH3 Domain, wherein:

• (i) said CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of DR5 mAb 1, and respectively comprise the amino acid sequences:
• SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, and said CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of DR5 mAb 1, and respectively comprise the amino acid sequences:
• SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11;
• or
• (ii) said CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of DR5 mAb 2, and, respectively comprise the amino acid sequences:
• SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16, and said CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of DR5 mAb 2, and respectively comprise the amino acid sequences:
• SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21;
• or
• (iii) said CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of hDR5 mAb 2 VL-3, and, respectively comprise the amino acid sequences:
• SEQ ID NO:
• 165, SEQ ID NO:15, and SEQ ID NO:16, and said CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of hDR5 mAb 2 VH-3, and respectively comprise the amino acid sequences:
• SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21.

A multivalent DR5-Binding Molecule that is a bispecific binding molecule, capable of simultaneously binding to two different epitopes of human Death Receptor 5 (DR5), wherein said multivalent DR5-Binding Molecule comprises four antigen-binding domains each capable of binding human DR5, and wherein at least one of said antigen-binding domains comprises three Light Chain CDR Domains (CDRL1, CDRL2 and CDRL3) and three Heavy Chain CDR Domains (CDRH1, CDRH2 and CDRH3) wherein:

• (i) said CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of DR5 mAb 1, and respectively comprise the amino acid sequences:
• SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, and said CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of DR5 mAb 1, and respectively comprise the amino acid sequences:
• SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11;
• or
• (ii) said CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of DR5 mAb 2, and, respectively comprise the amino acid sequences:
• SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16, and said CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of DR5 mAb 2, and respectively comprise the amino acid sequences:
• SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21;
• or
• (iii) said CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of hDR5 mAb 2 VL-3, and, respectively comprise the amino acid sequences:
• SEQ ID NO:165, SEQ ID NO:15, and SEQ ID NO:16, and said CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of hDR5 mAb 2 VH-3, and respectively comprise the amino acid sequences:
• SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21.